U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Lung Small Cell Carcinoma

MedGen UID:
1701768
•Concept ID:
C5205118
•
Neoplastic Process

Definition

Lung small cell carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Lung Small Cell Carcinoma

Professional guidelines

PubMed

Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y
Cancer Commun (Lond) 2024 Jan;44(1):23-46. Epub 2023 Nov 20 doi: 10.1002/cac2.12505. PMID: 37985191Free PMC Article
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D
J Clin Oncol 2022 Feb 10;40(5):492-516. Epub 2021 Dec 21 doi: 10.1200/JCO.21.02314. PMID: 34932393
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Recent clinical studies

Etiology

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Kato T, Casarini I, Cobo M, Faivre-Finn C, Hegi-Johnson F, Lu S, Özgüroğlu M, Ramalingam SS
Lung Cancer 2024 Jan;187:107414. Epub 2023 Nov 8 doi: 10.1016/j.lungcan.2023.107414. PMID: 38088015
Current and Future Treatment Options in the Management of Stage III NSCLC.
Li Y, Juergens RA, Finley C, Swaminath A
J Thorac Oncol 2023 Nov;18(11):1478-1491. Epub 2023 Aug 11 doi: 10.1016/j.jtho.2023.08.011. PMID: 37574133
Locally Advanced Lung Cancer.
Oh S, Botros GN, Patel M, Haigentz M, Patel E, Kontopidis I, Langenfeld J, Deek MP, Jabbour SK
Hematol Oncol Clin North Am 2023 Jun;37(3):533-555. Epub 2023 Apr 4 doi: 10.1016/j.hoc.2023.02.007. PMID: 37024391
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC
Clin Lung Cancer 2020 Mar;21(2):e84-e88. Epub 2019 Dec 28 doi: 10.1016/j.cllc.2019.12.006. PMID: 31948903
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Diagnosis

Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W, Xia Y
Cancer Commun (Lond) 2024 Jan;44(1):23-46. Epub 2023 Nov 20 doi: 10.1002/cac2.12505. PMID: 37985191Free PMC Article
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K
JAMA Netw Open 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. PMID: 38100106Free PMC Article
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T
Nat Med 2022 Sep;28(9):1831-1839. Epub 2022 Aug 22 doi: 10.1038/s41591-022-01933-w. PMID: 35995953Free PMC Article
Advances in systemic therapy for non-small cell lung cancer.
Miller M, Hanna N
BMJ 2021 Nov 9;375:n2363. doi: 10.1136/bmj.n2363. PMID: 34753715
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Therapy

Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI
Front Immunol 2022;13:823618. Epub 2022 Feb 9 doi: 10.3389/fimmu.2022.823618. PMID: 35222404Free PMC Article
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D
J Clin Oncol 2022 Feb 10;40(5):492-516. Epub 2021 Dec 21 doi: 10.1200/JCO.21.02314. PMID: 34932393
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Heymach JV, Mitsudomi T, Harpole D, Aperghis M, Jones S, Mann H, Fouad TM, Reck M
Clin Lung Cancer 2022 May;23(3):e247-e251. Epub 2021 Oct 10 doi: 10.1016/j.cllc.2021.09.010. PMID: 34819266
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC
Clin Lung Cancer 2020 Mar;21(2):e84-e88. Epub 2019 Dec 28 doi: 10.1016/j.cllc.2019.12.006. PMID: 31948903
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators
N Engl J Med 2017 Nov 16;377(20):1919-1929. Epub 2017 Sep 8 doi: 10.1056/NEJMoa1709937. PMID: 28885881

Prognosis

Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI
Front Immunol 2022;13:823618. Epub 2022 Feb 9 doi: 10.3389/fimmu.2022.823618. PMID: 35222404Free PMC Article
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC
Clin Lung Cancer 2020 Mar;21(2):e84-e88. Epub 2019 Dec 28 doi: 10.1016/j.cllc.2019.12.006. PMID: 31948903
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators
N Engl J Med 2018 Dec 13;379(24):2342-2350. Epub 2018 Sep 25 doi: 10.1056/NEJMoa1809697. PMID: 30280658
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Clinical prediction guides

Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches.
Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D, Hendriks LEL
Ann Oncol 2022 Sep;33(9):893-908. Epub 2022 Jun 28 doi: 10.1016/j.annonc.2022.06.013. PMID: 35777706
Immunotherapy in Lung Cancer: Current Landscape and Future Directions.
Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI
Front Immunol 2022;13:823618. Epub 2022 Feb 9 doi: 10.3389/fimmu.2022.823618. PMID: 35222404Free PMC Article
Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S, Okamoto I, Lee GW, Chen Y, Niho S, Mak G, Yao W, Shire N, Jiang H, Cho BC
Clin Lung Cancer 2020 Mar;21(2):e84-e88. Epub 2019 Dec 28 doi: 10.1016/j.cllc.2019.12.006. PMID: 31948903
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr, Choy H
J Clin Oncol 2020 Mar 1;38(7):706-714. Epub 2019 Dec 16 doi: 10.1200/JCO.19.01162. PMID: 31841363Free PMC Article
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N, Santana-Davila R, Molina JR
Mayo Clin Proc 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013. PMID: 31378236

Recent systematic reviews

The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.
Yang Z, Zhong W, Luo Y, Wu C
BMC Cancer 2023 Oct 10;23(1):962. doi: 10.1186/s12885-023-11472-3. PMID: 37817073Free PMC Article
Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review.
Allignet B, De Ruysscher D, Martel-Lafay I, Waissi W
Cancer Treat Rev 2023 Jul;118:102573. Epub 2023 May 19 doi: 10.1016/j.ctrv.2023.102573. PMID: 37210766
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, Dunn IF, Gaspar LE, Gatson NTN, Gondi V, Jordan JT, Lassman AB, Maues J, Mohile N, Redjal N, Stevens G, Sulman E, van den Bent M, Wallace HJ, Weinberg JS, Zadeh G, Schiff D
J Clin Oncol 2022 Feb 10;40(5):492-516. Epub 2021 Dec 21 doi: 10.1200/JCO.21.02314. PMID: 34932393
Lung cancer.
Neville AJ, Kuruvilla MS
BMJ Clin Evid 2010 Nov 30;2010 PMID: 21406127Free PMC Article
Lung cancer.
Neville A
BMJ Clin Evid 2009 Apr 21;2009 PMID: 19445746Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...